US equities
|
MU
$1,088.00
▲+0.00%
SNDK
$1,692.42
▲+0.00%
NVDA
$237.47
▲+0.00%
INTC
$113.12
▲+0.00%
PLTR
$194.12
▲+0.00%
SPCX
$167.60
▲+0.00%
AMD
$645.86
▲+0.00%
MSTR
$153.37
▲+0.00%
MU
$1,088.00
▲+0.00%
SNDK
$1,692.42
▲+0.00%
NVDA
$237.47
▲+0.00%
INTC
$113.12
▲+0.00%
PLTR
$194.12
▲+0.00%
SPCX
$167.60
▲+0.00%
AMD
$645.86
▲+0.00%
MSTR
$153.37
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Estrella Immunopharma, Inc.
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
August 11, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
August 03, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
July 29, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
July 24, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
May 05, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
ESLAW
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
March 23, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
ESLAW
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 09, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
ESLAW
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 03, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
January 06, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
ESLAW
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
January 05, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
December 04, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
November 03, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
October 06, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
June 05, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
June 03, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
May 29, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
March 05, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
February 19, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
ESLAW
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
September 27, 2024
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
ESLAW
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
August 14, 2024
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tickers
ESLA
ESLAW
